All stories tagged :

Pr Newswire

4DMT to Participate in Chardan’s 9th Annual Genetic Medicines Conference

Tháng 10 14

RSMC President’s Asia Tour: A Glimpse into the Future of Globalized...

1 năm ago

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule...

1 năm ago

The Westin Surabaya Introduces the Next Generation Heavenly® Bed

1 năm ago

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s...

1 năm ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR...

1 năm ago

Leading Indonesian digital bank, Jenius chooses Perx to transform its customer...

1 năm ago

ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary...

1 năm ago

Sight Sciences Announces the Release of its First Sustainability Report

1 năm ago

GLUCOTRACK TO PRESENT IN THE JUNE 2024 SIDOTI SMALL CAP CONFERENCE

1 năm ago

Telehouse Canada launches its first three data centres in Toronto

1 năm ago

1 2 3 … 758 759 760 761 762 763 Page 761 of 763

Featured

Opus Genetics to Participate in Chardan’s 9th Annual Genetic Medicines Conference

2 giờ ago

Hawx Services Celebrates Serving 14 States Across Nationwide

2 giờ ago

AICB Launches FSF Xcel: Malaysia’s First Industry-Wide Skills Assessment Platform to...

2 giờ ago

Morgan Stanley Raises JOYY (JOYY.US) Target Price from US$40 to US$62...

2 giờ ago

2 giờ ago

Opus Genetics to Participate in Chardan’s 9th Annual Genetic Medicines Conference

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that Ash...